Jw Life Science Corp
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed … Read more
Jw Life Science Corp (234080) - Total Liabilities
Latest total liabilities as of September 2025: ₩95.16 Billion KRW
Based on the latest financial reports, Jw Life Science Corp (234080) has total liabilities worth ₩95.16 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jw Life Science Corp - Total Liabilities Trend (2015–2024)
This chart illustrates how Jw Life Science Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jw Life Science Corp Competitors by Total Liabilities
The table below lists competitors of Jw Life Science Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Musti Group Oyj
HE:MUSTI
|
Finland | €288.33 Million |
|
ÖKOWORLD AG
F:VVV3
|
Germany | €24.57 Million |
|
Sogefi S.p.A.
LSE:0NV0
|
UK | €1.01 Billion |
|
Jutal Offshore Oil Services Ltd
PINK:JUTOF
|
USA | $902.66 Million |
|
Deltex Medical Group plc
PINK:DTXMF
|
USA | $2.93 Million |
|
Manas Enerji Yonetimi Sanayi & Ticaret AS
IS:MANAS
|
Turkey | TL624.23 Million |
|
UVAT Technology Co Ltd
TWO:3580
|
Taiwan | NT$690.32 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Jw Life Science Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jw Life Science Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jw Life Science Corp (2015–2024)
The table below shows the annual total liabilities of Jw Life Science Corp from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩124.88 Billion | +29.48% |
| 2023-12-31 | ₩96.44 Billion | -14.36% |
| 2022-12-31 | ₩112.61 Billion | +28.00% |
| 2021-12-31 | ₩87.97 Billion | +2.32% |
| 2020-12-31 | ₩85.98 Billion | +9.13% |
| 2019-12-31 | ₩78.79 Billion | -13.99% |
| 2018-12-31 | ₩91.60 Billion | -5.01% |
| 2017-12-31 | ₩96.43 Billion | -5.41% |
| 2016-12-31 | ₩101.94 Billion | +5.04% |
| 2015-12-31 | ₩97.05 Billion | -- |